Source: CureToday articles
As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.
Recent Content
- Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
- Novel Clonal Competition Assays Tool Can Personalize Treatment for Patients with Multiple Myeloma
- Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma
- New horizons in our understanding of precursor multiple myeloma and early interception
- Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
- Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma
- Blood test may predict response to CAR T-cell therapy in relapsed multiple myeloma
- Ninlaro Combo Delays Post-Transplant Progression in Relapsed Myeloma
- Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells
- Aurigene Oncology Limited announces promising results of Phase 1 study for India’s first trial for novel autologous CAR-T cell therapy for multiple myeloma